Lebrikizumab Delivered Significant Skin Clearance and Improved Disease Severity in Children With Moderate-to-Severe Atopic Dermatitis

Key Takeaways

• 63% achieved EASI‑75 versus 22% placebo
• 44% reached IGA 0/1 versus 15% placebo
• 35% reported ≥4‑point itch improvement
• 62% showed CDLQI ≥6‑point gain
• Safety profile aligns with adult data

Summary

Almirall reported that lebrikizumab met both co‑primary endpoints in the Phase 3 ADorable‑1 trial, with 63% of pediatric participants achieving EASI‑75 and 44% attaining clear or almost clear skin (IGA 0/1) after 16 weeks. Key secondary outcomes showed significant itch reduction, higher rates of EASI‑90, and quality‑of‑life improvements measured by CDLQI. The study enrolled 363 children and adolescents, comparing weight‑based lebrikizumab dosing to placebo on top of low‑to‑medium potency topical steroids. Safety remained consistent with the drug’s established profile, showing no new signals.

Pulse Analysis

The ADorable‑1 trial marks a pivotal step for lebrikizumab, the IL‑13‑targeting monoclonal antibody already approved for adults in Europe. By demonstrating robust efficacy in patients as young as six months, Almirall is extending the therapeutic reach of biologics into a demographic where treatment options are limited to topical agents and off‑label systemic drugs. The trial’s design—weight‑based dosing combined with standardized low‑to‑medium potency corticosteroids—mirrors real‑world practice, reinforcing the relevance of the outcomes for clinicians managing pediatric atopic dermatitis.

Beyond the headline efficacy numbers, the trial highlights meaningful patient‑centered benefits. Itch relief, captured by a ≥4‑point drop on the Pruritus NRS, translates into better sleep and reduced school absenteeism, while the CDLQI improvements reflect broader psychosocial gains. Such multidimensional outcomes are increasingly valued by payers and health technology assessment bodies, which are shifting toward value‑based reimbursement models that consider quality‑of‑life metrics alongside clinical endpoints.

Strategically, the data bolster Almirall’s position in the competitive biologics landscape, where rivals such as dupilumab and tralokinumab dominate adult markets. Securing pediatric indications could create a lifecycle extension and differentiate lebrikizumab as the first IL‑13‑specific agent with a dedicated pediatric label in Europe. The partnership with Eli Lilly for U.S. rights also opens pathways for global commercialization, potentially accelerating revenue growth and supporting Almirall’s broader pipeline of skin‑focused innovations.